Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Spring;11(2):107-16.
doi: 10.5812/ijem.5034. Epub 2013 Apr 1.

GnRH analogues in the prevention of ovarian hyperstimulation syndrome

Pilar Alama  1 , Jose Bellver, Carmen Vidal, Juan Giles
Affiliations

GnRH analogues in the prevention of ovarian hyperstimulation syndrome

Pilar Alama et al. Int J Endocrinol Metab. 2013 Spring.

Abstract

The GnRH analogue (agonist and antagonist GnRH) changed ovarian stimulation. On the one hand, it improved chances of pregnancy to obtain more oocytes and better embryos. This leads to an ovarian hyper-response, which can be complicated by the ovarian hyperstimulation syndrome (OHSS). On the other hand, the GnRH analogue can prevent the incidence of OHSS: GnRH antagonist protocols, GnRH agonist for triggering final oocyte maturation, either together or separately, coasting, and the GnRH analogue may prove useful for avoiding OHSS in high-risk patients. We review these topics in this article.

Keywords: GnRH Agonist; GnRH Antagonist; Ovarian Hyperstimulation Syndrome; Ovarian Stimulation; Prevention.

PubMed Disclaimer

Figures

Table 1.
Table 1.. Early Prevention Form
Table 2.
Table 2.. Late Prevention Form
See this image and copyright information in PMC

References

    1. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44(6):430–40. - PubMed
    1. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94(2):389–400. doi: 10.1016/j.fertnstert.2010.03.028. - DOI - PubMed
    1. Busso C, Fernandez-Sanchez M, Garcia-Velasco JA, Landeras J, Ballesteros A, Munoz E, et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod. 2010;25(4):995–1004. doi: 10.1093/humrep/deq005. - DOI - PMC - PubMed
    1. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24(12):3063–72. doi: 10.1093/humrep/dep291. - DOI - PMC - PubMed
    1. Abramov Y, Elchalal U, Schenker JG. Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril. 1998;70(6):1070–6. - PubMed

LinkOut - more resources